{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.42","upperLimit":"14.49","value":"13.73"},{"groupId":"OG001","lowerLimit":"10.94","upperLimit":"12.52","value":"11.63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"697"},{"groupId":"OG001","value":"727"}],"units":"Participants"}],"title":"All randomized participants"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.42","upperLimit":"14.82","value":"13.80"},{"groupId":"OG001","lowerLimit":"10.74","upperLimit":"12.25","value":"11.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"561"},{"groupId":"OG001","value":"607"}],"units":"Participants"}],"title":"Participants with PD-LI CPS ≥ 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.11","upperLimit":"16.23","value":"14.39"},{"groupId":"OG001","lowerLimit":"10.05","upperLimit":"12.12","value":"11.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"473"},{"groupId":"OG001","value":"482"}],"units":"Participants"}],"title":"Participants with PD-L1 CPS ≥ 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.63","upperLimit":"16.66","value":"15.01"},{"groupId":"OG001","lowerLimit":"9.89","upperLimit":"11.96","value":"10.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"316"},{"groupId":"OG001","value":"355"}],"units":"Participants"}],"title":"Participants with PD-L1 CPS ≥ 10"}],"denoms":[{"counts":[{"groupId":"OG000","value":"697"},{"groupId":"OG001","value":"727"}],"units":"Participants"}],"description":"Overall survival (OS), defined as the time from randomization to the time of death, in participants treated with Nivolumab plus Chemotherapy vs Chemotherapy with PD-L1 CPS ≥ 1, 10, and all randomized participants. CPS is defined as the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab + Xelox: Nivolumab 360 mg IV over 30 minutes on Day 1 of each treatment cycle, every 3 weeks + Oxaliplatin 130 mg/m2 IV on Day 1 of each treatment cycle + capecitabine 1000 mg/m2 orally twice daily (ie, 1000 mg/m2 in the morning and 1000 mg/m2 in the evening) on Days 1 to 14 of each treatment cycle, every 3 weeks\n\nNivolumab + Folfox: Nivolumab 240 mg IV over 30 minutes on Day 1 of each treatment cycle, every 2 weeks + Oxaliplatin 85 mg/m2 + leucovorin 400 mg/m2 + fluorouracil 400 mg/m2 IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours (or per local standard) daily on Days 1 and 2 of each treatment cycle, every 2 weeks","id":"OG000","title":"Arm 1: Nivolumab + Chemotherapy (XELOX or FOLFOX)"},{"description":"Chemotherapy (XELOX or FOLFOX): Xelox: Oxaliplatin 130 mg/m2 IV on Day 1 of each treatment cycle + capecitabine 1000 mg/m2 orally twice daily (ie, 1000 mg/m2 in the morning and 1000 mg/m2 in the evening) on Days 1 to 14 of each treatment cycle, every 3 weeks. Folfox: Oxaliplatin 85 mg/m2 + leucovorin 400 mg/m2 + fluorouracil 400 mg/m2 IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours (or per local standard) daily on Days 1 and 2 of each treatment cycle, every 2 weeks. Comparison group to Arm 1.","id":"OG001","title":"Arm 2a: Chemotherapy (XELOX or FOLFOX)"}],"paramType":"MEDIAN","populationDescription":"All randomized participants with available OS measurements in various subsets","reportingStatus":"POSTED","timeFrame":"From the date of randomization up to the date of death, up to approximately 17 months","title":"OS in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy","type":"SECONDARY","unitOfMeasure":"Months"}